Recombinant EGFR (Zalutumumab Biosimilar) antibody
Reactivity: Human
ELISA, FACS, WB
Host: Human
Monoclonal
2F8
unconjugated
Recombinant Antibody
-
- Target See all EGFR (Zalutumumab Biosimilar) products
- EGFR (Zalutumumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Human
-
Clonality
- Monoclonal
-
Conjugate
- This EGFR (Zalutumumab Biosimilar) antibody is un-conjugated
- Application
- ELISA, Flow Cytometry (FACS), Western Blotting (WB)
- Purpose
- Anti-EGFR [2F8 (Zalutumumab, HuMax-EGFR)], Human IgG1, kappa
- Specificity
- This antibody binds domain III of the human epidermal growth factor receptor (EGFR).
- Characteristics
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- Purification
- Protein A affinity purified
- Immunogen
- The original monoclonal antibody was generated by immunizing HuMAb mice with alternating A431 cells and purified EGFR administration.
- Clone
- 2F8
- Isotype
- IgG1 kappa
-
-
- Application Notes
- This antibody blocks the binding of EGF and TGF-α to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R-overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 μg/mL (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding cite (Bleeker et al., 2004). Phase I/II clinical trials and pharmacokinetic studies in patients with advanced squamous cell carcinoma of the head and neck revealsed that 2F8/HuMax-EGFR can be safely administered in doses upto 8 mg/kg (Bastholt et al., 2007) Antibody 2F8 binds the domain III of the EGFR and locks it into a very compact and inactice conformation. Biochemical analyses showed bivalent binding of 2F8 to provide potent inhibition of EGFR signaling (Beuren et al., 2008). EGFRvIII-specific CDC was significantly enhanced when zalutumumab was combined with a Fc-engineered variant of antibody MR1-1 (Klausz et al., 2011).
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- EGFR (Zalutumumab Biosimilar)
- Abstract
- EGFR (Zalutumumab Biosimilar) Products
- Background
- ERBB1, ERBB, Erb-B2, HER1, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
- UniProt
- P00533
-
You are here:
